Marcel O Bonn-Miller1, Sue Sisley2, Paula Riggs3, Berra Yazar-Klosinski4, Julie B Wang4, Mallory J E Loflin5,6, Benjamin Shechet2,4, Colin Hennigan4, Rebecca Matthews4, Amy Emerson4, Rick Doblin4. 1. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America. 2. Scottsdale Research Institute, Scottsdale, Arizona, United States of America. 3. School of Medicine, University of Colorado, Aurora, Colorado, United States of America. 4. Multidisciplinary Association for Psychedelic Studies, Santa Cruz, California, United States of America. 5. Center of Excellence for Stress and Mental Health & National Center for PTSD, VA San Diego Healthcare System, San Diego, California, United States of America. 6. San Diego School of Medicine, Department of Psychiatry, University of California, San Diego, California, United States of America.
Abstract
IMPORTANCE: There is a pressing need for development of novel pharmacology for the treatment of Posttraumatic Stress Disorder (PTSD). Given increasing use of medical cannabis among US military veterans to self-treat PTSD, there is strong public interest in whether cannabis may be a safe and effective treatment for PTSD. OBJECTIVE: The aim of the present study was to collect preliminary data on the safety and potential efficacy of three active concentrations of smoked cannabis (i.e., High THC = approximately 12% THC and < 0.05% CBD; High CBD = 11% CBD and 0.50% THC; THC+CBD = approximately 7.9% THC and 8.1% CBD, and placebo = < 0.03% THC and < 0.01% CBD) compared to placebo in the treatment of PTSD among military veterans. METHODS: The study used a double-blind, cross-over design, where participants were randomly assigned to receive three weeks of either active treatment or placebo in Stage 1 (N = 80), and then were re-randomized after a 2-week washout period to receive one of the other three active treatments in Stage 2 (N = 74). The primary outcome measure was change in PTSD symptom severity from baseline to end of treatment in Stage 1. RESULTS: The study did not find a significant difference in change in PTSD symptom severity between the active cannabis concentrations and placebo by the end of Stage 1. All three active concentrations of smoked cannabis were generally well tolerated. CONCLUSIONS AND RELEVANCE: The present study is the first randomized placebo-controlled trial of smoked cannabis for PTSD. All treatment groups, including placebo, showed good tolerability and significant improvements in PTSD symptoms during three weeks of treatment, but no active treatment statistically outperformed placebo in this brief, preliminary trial. Additional well-controlled and adequately powered studies with cannabis suitable for FDA drug development are needed to determine whether smoked cannabis improves symptoms of PTSD. TRIAL REGISTRATION: Identifier: NCT02759185; ClinicalTrials.gov.
RCT Entities:
IMPORTANCE: There is a pressing need for development of novel pharmacology for the treatment of Posttraumatic Stress Disorder (PTSD). Given increasing use of medical cannabis among US military veterans to self-treat PTSD, there is strong public interest in whether cannabis may be a safe and effective treatment for PTSD. OBJECTIVE: The aim of the present study was to collect preliminary data on the safety and potential efficacy of three active concentrations of smoked cannabis (i.e., High THC = approximately 12% THC and < 0.05% CBD; High CBD = 11% CBD and 0.50% THC; THC+CBD = approximately 7.9% THC and 8.1% CBD, and placebo = < 0.03% THC and < 0.01% CBD) compared to placebo in the treatment of PTSD among military veterans. METHODS: The study used a double-blind, cross-over design, where participants were randomly assigned to receive three weeks of either active treatment or placebo in Stage 1 (N = 80), and then were re-randomized after a 2-week washout period to receive one of the other three active treatments in Stage 2 (N = 74). The primary outcome measure was change in PTSD symptom severity from baseline to end of treatment in Stage 1. RESULTS: The study did not find a significant difference in change in PTSD symptom severity between the active cannabis concentrations and placebo by the end of Stage 1. All three active concentrations of smoked cannabis were generally well tolerated. CONCLUSIONS AND RELEVANCE: The present study is the first randomized placebo-controlled trial of smoked cannabis for PTSD. All treatment groups, including placebo, showed good tolerability and significant improvements in PTSD symptoms during three weeks of treatment, but no active treatment statistically outperformed placebo in this brief, preliminary trial. Additional well-controlled and adequately powered studies with cannabis suitable for FDA drug development are needed to determine whether smoked cannabis improves symptoms of PTSD. TRIAL REGISTRATION: Identifier: NCT02759185; ClinicalTrials.gov.
Authors: Jasmine Turna; William Simpson; Beth Patterson; Philippe Lucas; Michael Van Ameringen Journal: J Psychiatr Res Date: 2019-01-31 Impact factor: 4.791
Authors: Michelle J Bovin; Shimrit K Black; Paola Rodriguez; Carole A Lunney; Sarah E Kleiman; Frank W Weathers; Paula P Schnurr; James Spira; Terence M Keane; Brian P Marx Journal: Psychol Serv Date: 2018-05
Authors: Ravi K Das; Sunjeev K Kamboj; Mayurun Ramadas; Kishoj Yogan; Vivek Gupta; Emily Redman; H Valerie Curran; Celia J A Morgan Journal: Psychopharmacology (Berl) Date: 2013-01-10 Impact factor: 4.530
Authors: David Watson; Michael W O'Hara; Leonard J Simms; Roman Kotov; Michael Chmielewski; Elizabeth A McDade-Montez; Wakiza Gamez; Scott Stuart Journal: Psychol Assess Date: 2007-09
Authors: Bhanu Prakash Kolla; Lisa Hayes; Chaun Cox; Lindy Eatwell; Mark Deyo-Svendsen; Meghna P Mansukhani Journal: J Prim Care Community Health Date: 2022 Jan-Dec